随着减重药巨头诺和诺德重磅GLP-1类药物司美格鲁肽在中国的核心分子专利即将于3月到期，一大批中国本土的司美格鲁肽仿制药正在获批路上。据公开信息，目前国内市场上包括九源基因、丽珠集团、华东医药、齐鲁制药、正大天晴在内的十多家本土制药公司的司美格鲁肽仿制药有望在不久的将来上市，还有十余款处于三期临床，一场价格大战即将席卷。一位内分泌专家表示，随着更多仿制药的上市，减重药很快就会迎来“白菜价”时代。（第一财经）
case, the oddball System/3 card had a second life as the "Transaction Statement
。关于这个话题，WPS官方版本下载提供了深入分析
In defending herself and her business, Kennedy returns to the idea that seeking help with parenting—and paying for it—is not all that different from pursuing coaching of other kinds. “I’ve never heard anyone say that executive coaches make CEOs anxious, right? I don’t hear anyone saying money managers make people anxious with their finances, or basketball coaches or sports psychologists make athletes anxious in those fields.”
从我们入库企业的数量看，亿元和千万元级别是企业分布数量最多的两个区间，5029 家企业，占比超过八成（85.02%），研发投入合计7734.02 亿元，占比接近三成（28.50%）。